

*Research Article*

## Soluble CD163 is a Novel Diagnostic Marker for Spontaneous Bacterial Peritonitis in Patients with HCV Induced Liver Cirrhosis

Ahmed M. Ali\*, Elwy M. Soliman\*, Mahmoud R. Mohammed\*,  
Mahmoud S. Desoky\*\* and Emad A. Abdel-Naeem\*\*\*

\* Department of Internal Medicine, Minia University

\*\* Department of Tropical Medicine, Minia University

\*\*\*Department of Clinical Pathology, Minia University

### Abstract

**Background/Aims:** The diagnosis of spontaneous bacterial peritonitis (SBP) is based on a polymorphonuclear leukocytes (PMNs) exceeding  $250/\mu\text{L}$  in ascitic fluid. The aim of the study was to evaluate serum soluble CD 163 (sCD163) as an accurate diagnostic serum marker for detecting SBP. **Methods:** Forty patients with cirrhotic ascites were included. They were divided into a SBP group, including 20 patients, and a non-SBP group of 20 patients. Serum sCD163 was measured using an enzyme-linked immunosorbent assay. **Results:** Serum sCD163 was significantly higher in SBP patients than in non-SBP patients. At a cutoff value of  $3100\text{ ng/mL}$ , serum sCD 163 had 100% sensitivity and 90% specificity for detecting SBP. Serum sCD163 was positively correlated with deterioration of liver function in patients with liver cirrhosis. **Conclusions:** According to our findings, determination of serum sCD163 level appears to provide satisfactory diagnostic marker for the diagnosis of SBP.

**Keywords:** Spontaneous bacterial peritonitis, Soluble CD 163, Liver cirrhosis

### Introduction

Ascites is one of the most common complications of liver cirrhosis and it develops as a consequence of portal hypertension and splanchnic vasodilatation<sup>(1)</sup>. Spontaneous bacterial peritonitis (SBP) is one of the main infectious complications of cirrhosis and occurs in 8-30% of hospitalized patients with ascites<sup>(2)</sup>. The 1-year probability of development of the first episode of SBP in end-stage liver disease patients with ascites is around 10%<sup>(3)</sup>. SBP is defined as an infection of the previously sterile ascitic fluid in the absence of a visceral perforation and in the absence of an intra-abdominal inflammatory focus such as abscess, acute pancreatitis, or cholecystitis<sup>(4)</sup>. Also, the number of polymorphonuclear leukocytes (PMN) from the ascitic fluid obtained by paracentesis must exceed  $250\text{ cells/mm}^3$  and only one germ must be isolated in the bacteriological cultures<sup>(5)</sup>.

Infection and inflammation are often linked to the development of compli-

cations in cirrhosis, especially relating to portal hypertension. Portal hypertension increases bacterial translocation and endotoxaemia, which induces an inflammatory response in the liver and in the systemic circulation with subsequent activation of immune cells<sup>(1)</sup>. CD163, a highly expressed macrophage membrane protein, belongs to the scavenger receptor cysteine rich (SRCR) domain family with a short cytoplasmic tail, a transmembrane segment, and an extracellular domain. This macrophage receptor is a specific marker for macrophage activation. It is shed into the circulation in a soluble form (sCD163) after Toll-like receptor activation and the serum concentrations of sCD163 are accordingly elevated during conditions of macrophage activation and proliferation<sup>(6)</sup>. It is reported that CD163 showed anti-inflammatory effect in patients with liver failure<sup>(4)</sup>. Fabriek et al.,<sup>(3)</sup> founded that CD163 could enhance the host immunity as the innate immune receptor of gram-negative bacteria and gram-positive bacteria. Elevated circulating sCD163 has

been demonstrated in viral hepatitis, acute liver failure and cirrhosis<sup>(7)</sup>. Liver cirrhosis with ascites is often complicated by a hyperdynamic circulatory state. It has been postulated that intestinal bacterial overgrowth, altered gut permeability, and bacterial translocation, all common in cirrhosis with ascites, may exert continuous pressure on the immune system. This disturbance is thought to lead to activation of monocytes and lymphocytes and increased serum levels of proinflammatory cytokines such as tumor necrosis factor  $\alpha$  (TNF- $\alpha$ )<sup>(11)</sup>. To our knowledge, the roles of sCD163 have not been assessed in patients with SBP. We hypothesized that sCD163 would be associated with the development of SBP in cirrhotic patients with ascites. Also we assumed that soluble CD163 which is produced in serum as a result of macrophage activation in patients with SBP may be a promising diagnostic marker which is easily measured by ELISA. The aim of this study was to measure and compare the levels of sCD163 in patients with SBP and patients without SBP and to assess their role in detecting patients at high risk of developing SBP.

### Patients and methods

In this prospective study, we recruited 40 patients with ascites referred for paracentesis to the Internal and Tropical Medicine Departments of El-Minia University Hospital, Minia, Egypt, from March 2014 to January 2015. Twenty of these patients had cirrhotic ascites and had been admitted with SBP (cases) and 20 patients had cirrhotic ascites with no existing evidence of SBP (controls). Diagnosis of SBP was made on the basis of the presence of at least 200 cells/mL PMN in the ascitic fluid, with or without positive ascitic fluid culture, in the absence of secondary peritonitis and hemorrhagic ascites.

Exclusion criteria included patients with secondary causes of intra-abdominal sepsis (ascitic fluid protein  $>2.0$  g/dl), patients with tuberculous peritonitis,

patients with right-sided heart failure and diabetes mellitus, patients with renal impairment, rheumatoid arthritis, systemic lupus erythematosus and hepatocellular carcinoma.

All patients were subjected to complete history taking and thorough clinical examination. Pelviabdominal ultrasound examination was done for all patients. Liver profile and creatinine concentrations were measured on Hitachi 902 Chemistry autoanalyzer (Roche Diagnostics, Basel, Switzerland) using its commercially available reagents, complete blood picture was measured on CELLDYN Emerald cell counter (ABBOTT, Wiesbaden, Germany), serum sCD163 was measured quantitatively by enzyme-linked immunosorbent assay (ELISA) technique using (Human Soluble CD163\_sCD163\_ELISA Kit/ Glory Science Co., LTD).

This study was approved by the Ethical Committee of Minia University and all patients provided written informed consent prior to participation in any protocol-specific procedures. The study was conducted in accordance with the guidelines of the Helsinki Declaration

### Statistical analysis

All statistical analyses were performed using the SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA). Kolmogorov-Smirnov test was used to test distribution of data. Parametric data were expressed in mean  $\pm$  standard deviation. Student t-test and Mann-Whitney U test were used for intergroup comparisons.

Analysis of the receiver operator characteristics (ROC) and calculation of the area under the receiver operating characteristic curve (AUC) were used to evaluate serum sCD163 with maximum sensitivity and specificity for differentiation between ascitic patients with SBP and without SBP. Spearman correlation analysis was done between serum sCD163 and other laboratory and radiological parameters. A p-value of less than or equal 0.05 indicated statistical significance.

**Results**

The present study was carried out on 40 selected patients who presented ascites in patients with HCV induced liver cirrhosis; they were classified into two groups. Group I (cases group) included 20 patients with cirrhotic ascites with SBP (10 males and five females) with their mean age was 67.3±0.8. Group II (control group) included 20 patients with cirrhotic ascites without SBP (12 males and six females) with their mean age was 60.8±0.5. There was no significant differences regarding the age and sex between SBP and non-SBP patients. Serum levels of ALT, bilirubin, creatinine and prothrombin time exhibited significantly higher values in patients SBP when compared to ascitic patients without SBP. Serum albumin levels exhibited significant lower values in patients with patients with SBP when compared to patients with non-complicated ascites. Ultrasonographic measures of portal vein revealed that portal vein diameter was larger in patients of group I (SBP) compared to patients the control groups. These differences however were not significant statistically. The splenic longest axis diameter was significantly higher in patients with SBP compared to patients with non-complicated ascites with P value of 0.003.

Serum sCD163 showed significantly higher levels in patients with SBP when compared to patients with non-complicated ascites (3271±717 vs. 1414±300, P value <0.001). Peripheral PMN showed significantly increased values in SBP group compared to control group (12.0±3.2 vs. 6.13±1.1, P value p<0.001). Moreover there was a significant positive correlation between serum sCD163 and PMNs in cirrhotic patients with SBP (r = 0.71, P value 0.008) (figure 1)

Also a significant positive correlation was found between increased levels of sCD163 and worsening of liver function in patient with SBP. This was evident by significantly positive correlation between serum levels of sCD163 and serum levels of ALT, AST, serum bilirubin and INR and significantly negative correlation between serum levels of sCD163 and serum albumin in patients with SBP (Table 2). ROC curve analysis of serum sCD163 showed that at a cutoff value of >3100 ng/ml serum sCD163 had a diagnostic sensitivity of 100% and specificity 90% for detecting SBP (AUC= 0.983). Concerning peripheral PMN cell count, it was found that at a cutoff value of 10,300/mm<sup>3</sup>, PMN cell count had 80% sensitivity and 30% specificity for detecting SBP (AUC= 0.521)

**Table (1): demographic, Laboratory and radiological findings in the studied groups**

Variable	Group I (SBP) N=20	Group II (Ascites without SBP) N=20	P value
Age (years)	67.3 ± 0.8	60.8 ± 0.5	0.70
Gender Male/Female	10 (50%) / 10 (50%)	12 (60%) / 8 (40%)	0.987
ALT (IU/L)	77.37 ± 78.04	51 ± 27.79	0.04
AST (IU/L)	79.24 ± 110.7	71.42 ± 27.40	0.7
Albumin (g/dl)	2.07 ± 0.94	2.92 ± 0.73	0.024
Bilirubin (mg/d)	2.04 ± 0.29	1.18 ± 0.24	0.001
Creatinine (mg/dl)	1.37 ± 0.73	1.08 ± 0.37	0.02
Prothrombin time (sec)	20 ± 1.4	17 ± 1.1	0.04
PMNs/mm <sup>3</sup>	12.0 ± 3.2	6.13 ± 1.1	<0.001
sCD163 (ng/ml)	3271 ± 717	1414 ± 300	<0.001
PV diameter (mm)	13.43 ± 2.07	12.44 ± 2.08	0.007
Splenic longest axis (mm)	172.06 ± 20.3	148.80 ± 32.79	0.003

Data are presented as the mean ± SD or number (%).

SBP, spontaneous bacterial peritonitis; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; PMN, Polymorphonuclear leukocytes; PV diameter, Portal vein diameter

Table (2): Correlation of mean sCD163 with laboratory and radiological findings

Variable	Correlation coefficient (r)	P. value
PMN/mm <sup>3</sup>	0.71	0.008
AST (U/L)	0.64	0.04
ALT (U/L)	0.53	0.03
Albumin (g/dl)	-0.30	0.02
Billirubin (mg/d)	0.36	0.01
Prothrombin time (sec)	0.40	0.01
Portal vein diameter (mm)	0.61	0.04
Splenic longest axis (mm)	0.71	0.01




Figure (1): Correlation between PMN cell count and sCD163 level in patients with SBP

Table (3): Receiver Operator Characteristics Curve Analysis of Serum s CD163 and PMN in patients with and without SBP

variable	AUC	Cut-off	Sensitivity (%)	Specificity (%)
sCD163	0.983	>3100	100	90
PMNs	0.521	>20000	80	30




Figure (2): Receiver operating characteristic curves of serum sCD163 and PMNs in detecting SBP in cirrhotic patients.

## Discussion

SBP is one of the most common complications which occur in patients with cirrhosis and ascites. Complication of cirrhotic ascites arising most frequently in those patients with advanced liver disease, and it is characterized by spontaneous infection of the ascitic fluid without intra-abdominal sources of sepsis<sup>(1)</sup>.

SBP is an important cause of morbidity and mortality in cirrhotic patients with ascites. SBP is estimated to affect 10% to 30% of cirrhotic patients hospitalized with ascites<sup>(1)</sup>. Rapid and proper diagnosis of SBP can prevent death although mortality according to this complication is near 30-50%<sup>(1)</sup>.

The diagnosis of SBP is still based on diagnostic paracentesis<sup>(1)</sup>. It is an invasive maneuver with some complications. Therefore, there is a need for other noninvasive diagnostic tools.

SBP pathogenesis in patients with cirrhosis is considered to be the main consequence of bacterial translocation (BT). The BT is the process through which viable or nonviable bacteria and bacterial products (bacterial DNA or endotoxins) cross the intestinal lumen and come into the mesenteric lymph nodes or extra-intestinal. Bacterial translocation also is involved in increasing the hyperdynamic state of cirrhosis and in aggravation of hemostasis disorders<sup>(1)</sup>.

Other alternative method using mean platelet volume, C-reactive protein, and white blood cell levels measurement can be considered as an accurate diagnostic test in predicting SBP, possibly because of a continuous systemic inflammatory response<sup>(1)</sup>.

Soluble CD163 which is produced in serum as a result of macrophage activation is found to be increased in liver cirrhosis and portal hypertension but not yet assessed in patients with SBP. In this study, there is a significant increase in serum sCD163 in SBP versus non-SBP group.

Our study confirmed that there is positive correlation between the level of soluble cd163 and portal vein diameter and splenic

longest axis, these finding may be in accordance with Waidmann et al.,<sup>(1)</sup> who showed sCD163 correlates strongly with the hepatic venous pressure gradient (HVPG) and is thereby a good indicator of portal hypertension. Holland-Fischer et al.,<sup>(1)</sup> also reported that Hepatic kupffer cells are activated in cirrhotic patients in parallel with their portal hypertension and sCD163 is a sensitive marker of macrophages activation that positively correlated with the degree of portal hypertension in cirrhotic patients.

The present results show that patients of SBP had significant higher biochemical parameters than patients without SBP and our results was in agreement with Rizk et al.,<sup>(1)</sup> who found that there was significant increase in, AST and creatinine in the SBP group versus the non-SBP group. And also with Wei et al.,<sup>(1)</sup> who found similar results as regard increased levels of ALT, AST, bilirubin, INR in SBP group as compared with the non SBP group.

In our patients, we reported that at a cut off value of > 3100 ng/ml serum s CD163 had a diagnostic sensitivity of 100% and specificity 90% for detecting SBP. Moreover, there is a positive correlation between serum sCD163 and serum PMN cell count and deterioration of liver function in cirrhotic patients with ascites supported the hypothesis that, serum sCD163, being a marker of macrophage activation, could reflect ongoing systemic inflammatory responses in cirrhotic patients with SBP.

The cornerstone for the diagnosis of SBP stills the ascitic fluid analysis with the PMN cell count. Albillos et al.,<sup>(1)</sup> reported that an ascitic fluid PMN count greater than 500/mm<sup>3</sup> had specificity and sensitivity of 98% and 90%, respectively. In our cirrhotic patients with ascites, we found high specificity and sensitivity for serum sCD163 levels in patients with SBP, as discussed before. From our point of view, these values may be considered as an accurate and rapid method for detection of SBP in clinical practice and have similar accuracy in the determination of the PMN cell counts in ascitic fluid.

## Conclusion

This prospective study evaluated the diagnostic utility of measuring serum sCD163 to identify patients with SBP and conclude that patients with SBP had higher serum sCD163 than ascitic patients without SBP; this finding indicates that serum sCD163 correlate well and reliably with ascitic PMN cell count. Indeed, serum sCD163 may serve as a surrogate marker for PMN count and would be valuable for routine SBP screening as a noninvasive rapid and accurate assay.

## References

- 1- Lee JM, Han KH, Ahn SH, et al. Ascites and spontaneous bacterial peritonitis. *J Gastroenterol Hepatol* 2009; 24:1494-1503.
- 2- Strauss E, Caly WR. Spontaneous bacterial peritonitis: a therapeutic update. *Expert Rev Anti Infect Ther* 2006; 4:249-260.
- 3- Angeloni S, Leboffe C, Parente A, et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. *World J Gastroenterol* 2008; 14:2707-2712.
- 4- Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. *Eur J Gastroenterol Hepatol* 2005; 17:2731.
- 5- Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. *Hepatology* 2003; 38:208-216.
- 6- Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. *Lancet* 1999; 353:139-42.
- 7- Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Grønbaek H, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S. *Aliment Pharmacol Ther*. 2012 Jul; 36(7):173-80.
- 8- Soluble CD163 from activated macrophages predicts mortality in acute liver failure. Møller HJ, Grønbaek H, Schiødt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM, U.S. Acute Liver Failure Study Group. *J Hepatol*. 2007 Nov; 47(5):671-6.
- 9- The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Fabrick BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD, van den Berg TK. *Blood*. 2009 Jan 22; 113(4):887-92.
- 10- Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, Ruiz-del-Arbol L, Alvarez-Mon M.; Increased Lipopolysaccharide Binding Protein in Cirrhotic Patients With Marked Immune and Hemodynamic Derangement: *Hepatology*. 2003 Jan; 37(1):208-17.
- 11- Ribeiro Tarsila CR, Julio MF Chebli; Mario Kondo, Pedro Duarte Gaburri, Liliana Andrade Chebli, and Ana Cristina Amaral Feldner; Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication? *Ther Clin Risk Manag*. 2008 Oct; 4(5): 919-920.
- 12- Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis: in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. *Am J Gastroenterol* 2001; 96:1232-1236.
- 13- Farahmand, Fatemeh, Mohammad Eshagh Roze, Sedighe Shams, Mahsa Ghajarzadeh; Diagnosis of Spontaneous Bacterial Peritonitis in Children by Reagent Strips. *Acta Med Iran*. 2013 Mar 16; 51(7):120-8.
- 14- Rimola A, Gracia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. *J Hepatol* 2000; 32:142-153.
- 15- Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. *Hepatology* 2005; 41:422-433.
- 16- Abdel-Razik A, Eldars W, Rizk E. Platelet indices and inflammatory markers as diagnostic predictors for ascitic fluid infection. *Eur J Gastroenterol Hepatol* 2014; 26:1342-1347.
- 17- Waidmann O, Brunner F, Herrmann E, Zeuzem S, et al, (2013) ; Macrophage activation is a prognostic parameter for

- variceal bleeding and overall survival in patients with liver cirrhosis. *J Hepatol*; 2018; 906-961.
- 18- Grønbech H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, et al. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. *Gut* 2011; 60: 1389-1393.
- 19- Rizk, Ehsan, Rasha Elzehery , Sahar Zakaria , Ahmed Abdel-Razik, Dina Elhammady ; Ascitic Fluid Calprotectin and Serum C-Reactive Protein as Diagnostic Markers for Spontaneous Bacterial Peritonitis Afro-Egypt *J Infect Endem Dis*; 4(3): 117-120.
- 20- Wei Fang Fang, Xiaohong Zhang, Zhen Xu and Shaoquan Zhang ; New Markers to Explore Spontaneous Bacterial Peritonitis. *J Mol Biomark Diagn*, 2016
- 21- Albillos A, Cuervas-Mons V, Millán I, et al. Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis. *Gastroenterology* 1990; 98: 134-140.